Ticker brief
OCUL OCULAR THERAPEUTIX INC
Consumer, Non-cyclical · Pharmaceuticals
last close
$10.36
1 day
-4.3%
14 days
+3.2%
mkt cap
$2.1B
signals 14d
29
authors 14d
11
crowd 14d
+0.9σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 59% cheap · 3 pctile own 1y | IV/HV 1.13× (as of 2026-08-26) |
| Skew — 25Δ RR 30d | +0.148 96 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +0.92 elevated | 5-session Δ +0.25 (as of 2026-07-07) |
| OI alarm | quiet | last alarm 2026-02-25 (z=3.0) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-16 → 2026-08-28 · now +0.35 (−1 bearish … +1 bullish)
Who spoke11
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -3.01 | 16 | +0.43 |
| @adamfeuerstein | A | +1.41 | 3 | +0.17 |
| @Brad_E_Schulz | C | · | 2 | +0.00 |
| @jbulltard1 | C | +0.26 | 1 | +0.60 |
| @OpenOutcrier | C | · | 1 | +0.40 |
| @PrismMarketView | C | · | 1 | +0.40 |
| @PrismDM | A | -2.10 | 1 | +0.40 |
| @OptionsFlowBoss | C | · | 1 | +0.35 |
| @Sarge986 | C | +0.46 | 1 | +0.20 |
| @cfaryanoconnell | C | -1.48 | 1 | -0.15 |
| @ClassicRoy | C | -1.52 | 1 | +0.00 |
Recent signals29of 29 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @semodough | +0.35 | Expresses confidence in Ocular Therapeutix based on Peter Kaiser's development leadership. | — | tweet ↗ |
| 2026-08-27 | @semodough | +0.40 | Piper reiterates Buy with a $31 target and describes regulatory and commercialization milestones. | -4.3% | tweet ↗ |
| 2026-08-21 | @semodough | +0.45 | Suggests retinal-specialist enthusiasm and trust in AXPAXLI may be increasing. | -6.5% | tweet ↗ |
| 2026-08-21 | @semodough | +0.50 | Argues diabetic-retinopathy use adds upside and cites $2.3B modeled peak sales. | -6.5% | tweet ↗ |
| 2026-08-21 | @semodough | +0.15 | Recommends an OCUL Piper webcast after EYPT data but provides little standalone thesis. | -6.5% | tweet ↗ |
| 2026-08-21 | @semodough | +0.40 | BofA names OCUL a 2026 top pick with Buy and $27 target while highlighting an on-track NDA filing. | -6.5% | tweet ↗ |
| 2026-08-19 | @semodough | +0.65 | Cowen analysis argues OCUL's SOL-R screening design reduces variability and derisks non-inferiority. | -11.7% | tweet ↗ |
| 2026-08-18 | @semodough | +0.40 | Cowen rates OCUL Buy with a $20 target and highlights limited near-term class competition. | -5.9% | tweet ↗ |
| 2026-08-18 | @ClassicRoy | +0.00 | Reports increasing unusual put-option volume across a broad ticker screen. | -5.9% | tweet ↗ |
| 2026-08-18 | @cfaryanoconnell | -0.15 | Reports increasing unusual put-option volume; ticker list truncated to six. | -5.9% | tweet ↗ |
| 2026-08-18 | @Sarge986 | +0.20 | Says there are additional reasons to own RKLB while tagging two other names. | -5.9% | tweet ↗ |
| 2026-08-18 | @semodough | +0.45 | References Raymond James's best-case scenario for OCUL. | -5.9% | tweet ↗ |
| 2026-08-17 | @semodough | +0.40 | Baird sets a $30 OCUL target as a rival's pivotal miss improves Axpaxli's competitive position. | -2.7% | tweet ↗ |
| 2026-08-17 | @semodough | +0.45 | Baird doubts Duravyu's approvability, increasing the likelihood OCUL's Axpaxli becomes the only TKI insert. | -2.7% | tweet ↗ |
| 2026-08-17 | @Brad_E_Schulz | +0.00 | Lists stocks gaining at least 4% on elevated volume; capped at the first six names. | -2.7% | tweet ↗ |
| 2026-08-17 | @semodough | +0.75 | Claims OCUL's AXPAXLI is far more potent and uses a much smaller needle than EYPT's product | -2.7% | tweet ↗ |
| 2026-08-17 | @adamfeuerstein | +0.35 | Reports disappointing EYPT study results and implies competitive benefit for OCUL. | -2.7% | tweet ↗ |
| 2026-08-17 | @OptionsFlowBoss | +0.35 | Quantifies unusual bullish options volume across several stocks. | -2.7% | tweet ↗ |
| 2026-08-17 | @Brad_E_Schulz | +0.00 | Lists stocks up at least 4% on elevated average volume; capped at the first six names. | -2.7% | tweet ↗ |
| 2026-08-17 | @PrismDM | +0.40 | Reports EYPT's pivotal trial miss and the resulting positive read-through and price move for OCUL. | -2.7% | tweet ↗ |
| 2026-08-17 | @PrismMarketView | +0.40 | EyePoint's DURAVYU missed its pivotal primary endpoint, benefiting competitor Ocular. | -2.7% | tweet ↗ |
| 2026-08-17 | @semodough | +0.45 | Highlights 27M shares short ahead of conferences, an FDA meeting, and an AXPAXLI BLA | -2.7% | tweet ↗ |
| 2026-08-17 | @adamfeuerstein | -0.35 | Suggests both companies' data reinforce the strength of incumbent Eylea rather than their products. | -2.7% | tweet ↗ |
| 2026-08-17 | @OpenOutcrier | +0.40 | Ocular rose as competitor EyePoint's DURAVYU missed its wet-AMD trial primary endpoint. | -2.7% | tweet ↗ |
| 2026-08-17 | @jbulltard1 | +0.60 | Recaps a previously flagged risk reversal after OCUL rose 15% and EYPT fell 70%. | -2.7% | tweet ↗ |
| 2026-08-17 | @semodough | +0.15 | Questions whether EYPT's 12-gauge delivery needle contributes to issues versus OCUL's 25-gauge injection. | -2.7% | tweet ↗ |
| 2026-08-17 | @adamfeuerstein | +0.50 | OCUL rose 16% and was halted after competitor EYPT's clinical miss. | -2.7% | tweet ↗ |
| 2026-08-17 | @semodough | +0.35 | Anticipates a good day for OCUL while urging management to accelerate its BLA filing. | -2.7% | tweet ↗ |
| 2026-08-16 | @semodough | +0.60 | Reports WB's Outperform rating and $32 fair value based on Axpaxli's de-risked profile and launch outlook. | +3.2% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.